Clinical trial · Observational
Antidiabetic Medications and Risk of Cancer
NCT07628556CI-TRIAL-00113757completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A retrospective analysis was conducted based on data of the National Health Insurance Fund in Hungary. Overall cancer risk and site-specific cancer risks were analysed in a target trial emulation design when comparing all available antidiabetic therapies to MET and monotherapies and primary combination therapies against each other. The model used in the analysis was corrected for age, gender, co-morbidities, selected cardiovascular medications and inpatient and outpatient visits.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DPP-4 inhibitor | Drug | — | UNRESOLVED |
| GLP-1 Receptor Agonists | Drug | — | UNRESOLVED |
| insulin | Drug | — | UNRESOLVED |
| MET + DPP-4 inhibitor | Drug | — | UNRESOLVED |
| Metformin | Drug | Metformin | ALIAS |
| MET + GLP-1RA | Drug | — | UNRESOLVED |
| MET + INS | Drug | — | UNRESOLVED |
| MET + SGLT2i | Drug | — | UNRESOLVED |
| MET + SU | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Type 2 diabetes mellitus
- interventionNames
- Drug: Metformin
- Drug: sulphonylurea
- Drug: DPP-4 inhibitor
- Drug: GLP-1 Receptor Agonists
- Drug: SGLT-2 inhibitor
- Drug: insulin
- Drug: MET + SU
- Drug: MET + DPP-4 inhibitor
- Drug: MET + GLP-1RA
- Drug: MET + SGLT2i
- Drug: MET + INS
Primary outcomes (1)
- measure
- Overall cancer risk
- timeFrame
- 2016-2022
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Type 2 diabetes mellitus * Antidiabetic medication initiators Exclusion Criteria: * Antidiabetic prescription in the previous 5 years * Recent pancreatectomy (previous or subsequent 90 days after inclusion)
References
Publications (0)
Data not yet available
No reference posted for this study.